Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Mar;64(3):513-516.
doi: 10.1111/ijd.17552. Epub 2024 Oct 25.

A woman with mycosis fungoides, vitiligo, and a new hand nodule

Joelle Feghali  1   2 , Leore Lavin  3   4 , Spencer Ng  5 , Konstantinos Linos  5 , Shamir Geller  3
Affiliations
Case Reports

A woman with mycosis fungoides, vitiligo, and a new hand nodule

Joelle Feghali et al. Int J Dermatol. 2025 Mar.

Abstract

A 70-year-old African American female with a history of stage IV mycosis fungoides in remission presented with a gradually enlarging, red, ulcerated nodule on her right dorsal hand. The lesion was biopsied, and it showed intraepidermal proliferation with cytologic atypia and increased vasculature in the papillary dermis. Immunohistochemical staining indicated a yes-associated protein 1 (YAP1) rearrangement, confirmed by RNA sequencing, revealing a YAP1::MAML2 (mastermind-like transcriptional coactivator 2) fusion. The lesion was diagnosed as an eccrine porocarcinoma (EPC). The occurrence of EPCs following radiotherapy or trauma has been documented. This case highlights the importance of considering EPCs in patients with extensive skin treatments and immunosuppression history.

Keywords: eccrine; mycosis fungoides; skin cancer; skin of color (SOC); vitiligo.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None.

References

    1. Tsiogka A, Koumaki D, Kyriazopoulou M, Liopyris K, Stratigos A, Gregoriou S. Eccrine Porocarcinoma: A Review of the Literature. Diagnostics (Basel). 2023. Apr 16;13(8):1431. doi: 10.3390/diagnostics13081431. - DOI - PMC - PubMed
    1. Sekine S, Kiyono T, Ryo E, Ogawa R, Wakai S, Ichikawa H, Suzuki K, Arai S, Tsuta K, Ishida M, Sasajima Y, Goshima N, Yamazaki N, Mori T. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. J Clin Invest. 2019. May 30;129(9):3827–3832. doi: 10.1172/JCI126185. - DOI - PMC - PubMed
    1. Salih AM, Kakamad FH, Baba HO, et al. Porocarcinoma; presentation and management, a meta-analysis of 453 cases. Ann Med Surg (Lond). 2017;20:74–79. Published 2017 Jun 20. doi:10.1016/j.amsu.2017.06.027 - DOI - PMC - PubMed
    1. Russell-Goldman E, Hornick JL, Hanna J. Utility of YAP1 and NUT immunohistochemistry in diagnosing porocarcinoma. J Cutan Pathol. 2021. Mar;48(3):403–410. doi: 10.1111/cup.13924 - DOI - PubMed
    1. Snow JT, Georgantzoglou N, Green DC, et al. Molecular analysis of NUT-positive poromas and porocarcinomas identifies novel break points of YAP1::NUTM1 fusions. J Cutan Pathol. 2022;49(10):850–858. doi:10.1111/cup.14265 - DOI - PubMed

Publication types

MeSH terms

Substances